Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Point of Care Tests to Help Reduce Overuse of Antibiotics

By HospiMedica International staff writers
Posted on 27 Jan 2025

The misuse of antibiotics—such as taking them unnecessarily, for too long, or in incorrect doses—leads to antimicrobial resistance (AMR), making infections harder to treat and increasing the risks of severe illness and death. More...

AMR causes 700,000 global deaths annually, and many people either expect antibiotics from doctors or misuse them by not following prescribed dosages. Doctors face challenges in prescribing antibiotics due to diagnostic uncertainty, patient self-diagnosis, and limited resources. Now, two new tests for bacterial infections could help reduce the overuse of antibiotics for common respiratory illnesses.

Researchers at Deakin University (Victoria, Australia) are leading trials of the two new tests involving a simple finger prick or throat swab that provide immediate results to distinguish between bacterial and viral infections. This can enable more accurate diagnoses and targeted treatments, potentially reducing unnecessary antibiotic prescriptions. In international trials conducted earlier, the finger prick test has already shown promise, while early results from the latest trial indicate a reduction of antibiotic use by up to 30%. This test can help doctors determine if common respiratory infections are bacterial or viral, ensuring antibiotics are only prescribed when necessary.

The second test, a throat swab, allows doctors to quickly identify if a sore throat is caused by Strep A bacteria, a common source of throat infections. Despite Strep A being responsible for only 15 to 20% of sore throats, antibiotics are often overprescribed in 70% of cases. Proper diagnosis and early treatment are critical, especially in children, as Strep A can lead to severe complications like rheumatic heart disease. This throat swab test will optimize antibiotic treatment for Strep A. A feasibility trial conducted in 2024 with 200 patients across five clinics, followed by a pilot trial in 2025 with 400 patients, aims to further assess the test’s effectiveness in reducing antibiotic overuse. Both these trials hold the potential to significantly improve the responsible use of antibiotics.

“This work is trying to improve the capacity of GPs and community pharmacists with point-of-care diagnostic testing services,” said Dr. Sajal Saha, Research Fellow in the Centre for Innovation in Infectious Disease and Immunology Research. “This will help prescribers better understand the severity of infections or confirm bacterial infections for some respiratory infections during patient consultations and prescribe antibiotics accordingly.”

Related Links:
Deakin University


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.